These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21423645)

  • 21. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
    Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.
    West ES; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Bailey R; Foster A; Mabey D; West SK
    Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):83-7. PubMed ID: 15623758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
    Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constant ocular infection with Chlamydia trachomatis predicts risk of scarring in children in Tanzania.
    Wolle MA; Muñoz BE; Mkocha H; West SK
    Ophthalmology; 2009 Feb; 116(2):243-7. PubMed ID: 19091415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
    Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.
    Edwards T; Harding-Esch EM; Hailu G; Andreason A; Mabey DC; Todd J; Cumberland P
    Trop Med Int Health; 2008 Apr; 13(4):556-65. PubMed ID: 18282237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
    Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
    Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
    Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.
    Oldenburg CE; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Gaynor BD; Keenan JD; Lietman TM
    Am J Trop Med Hyg; 2018 Feb; 98(2):389-395. PubMed ID: 29260659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mass treatment with azithromycin for trachoma control: participation clusters in households.
    Ssemanda EN; Munoz B; Harding-Esch EM; Edwards T; Mkocha H; Bailey RL; Sillah A; Stare D; Mabey DC; West SK;
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
    Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
    PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trachoma and ocular Chlamydia trachomatis rates in children in trachoma-endemic communities enrolled for at least three years in the Tanzania National Trachoma Control Programme.
    Mkocha H; Munoz B; West S
    Tanzan J Health Res; 2009 Jul; 11(3):103-10. PubMed ID: 20734706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [No Abstract]   [Full Text] [Related]  

  • 36. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
    Stare D; Harding-Esch E; Munoz B; Bailey R; Mabey D; Holland M; Gaydos C; West S
    Ophthalmic Epidemiol; 2011 Feb; 18(1):20-9. PubMed ID: 21275593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serology for trachoma surveillance after cessation of mass drug administration.
    Martin DL; Bid R; Sandi F; Goodhew EB; Massae PA; Lasway A; Philippin H; Makupa W; Molina S; Holland MJ; Mabey DC; Drakeley C; Lammie PJ; Solomon AW
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting antibiotics to households for trachoma control.
    Blake IM; Burton MJ; Solomon AW; West SK; Basáñez MG; Gambhir M; Bailey RL; Mabey DC; Grassly NC
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e862. PubMed ID: 21072225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Alexander ND; Sillah A; Faal H; West SK; Foster A; Johnson GJ; Mabey DC; Bailey RL
    Lancet; 2005 Apr 9-15; 365(9467):1321-8. PubMed ID: 15823382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali.
    Schémann JF; Guinot C; Traore L; Zefack G; Dembele M; Diallo I; Traore A; Vinard P; Malvy D
    Acta Trop; 2007 Jan; 101(1):40-53. PubMed ID: 17239332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.